Translational Development Acquisition (TDACU) Liabilities and Shareholders Equity (2023 - 2026)

Translational Development Acquisition has reported Liabilities and Shareholders Equity for 4 years, with the latest figure at $183.3 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 3.82% year-over-year to $183.3 million; the trailing twelve-month figure through Mar 2026 stood at $723.2 million (up 105.69% YoY), and the FY2025 full-year result was $181.7 million, up 3.83% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $183.3 million, up from $181.7 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $183.3 million in Q1 2026, with the low at $2021.0 in Q4 2023.
• Historically, Liabilities and Shareholders Equity has averaged $153.5 million across 4 years, with a median of $178.2 million in 2025.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity soared 8659008.31% — and 2026, when it grew 3.82%.
• Translational Development Acquisition's Liabilities and Shareholders Equity stood at $2021.0 in 2023, then soared by 8659008.31% to $175.0 million in 2024, then rose by 3.83% to $181.7 million in 2025, then rose by 0.91% to $183.3 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $183.3 million (Q1 2026), $181.7 million (Q4 2025), and $180.0 million (Q3 2025), per Business Quant data.